title: An Immune-Modulating Diet in Combination with Chemotherapy Prevents Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice.
abstract: Cancer cachexia is characterized by muscle wasting caused partly by systemic inflammation. We previously demonstrated an immune-modulating diet (IMD), an enteral diet enriched with immunonutrition and whey-hydrolyzed peptides, to have antiinflammatory effects in some experimental models. Here, we investigated whether the IMD in combination with chemotherapy could prevent cancer cachexia in colon 26 tumor-bearing mice. Forty tumor-bearing mice were randomized into 5 groups: tumor-bearing control (TB), low dose 5-fluorouracil (5-FU) and standard diet (LF/ST), low dose 5-FU and IMD (LF/IMD), high dose 5-FU and standard diet (HF/ST) and high dose 5-FU and IMD (HF/IMD). The ST and IMD mice received a standard diet or the IMD ad libitum for 21 days. Muscle mass in the IMD mice was significantly higher than that in the ST mice. The LF/IMD in addition to the HF/ST and HF/IMD mice preserved their body and carcass weights. Plasma prostaglandin E2 levels were significantly lower in the IMD mice than in the ST mice. A combined effect was also observed in plasma interleukin-6, glucose, and vascular endothelial growth factor levels. Tumor weight was not affected by different diets. In conclusion, the IMD in combination with chemotherapy prevented cancer cachexia without suppressing chemotherapeutic efficacy.
authors.affiliation: a Nutrition Research Department, Food Science Research Laboratories, Meiji Co., Ltd. , Kanagawa , Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Nakamura
authors.forename: Akina
authors.initials: A
authors.lastname: Sasayama
authors.forename: Takeshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Taketo
authors.initials: T
authors.lastname: Yamaji
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D002100:Cachexia / Q000628:therapy*; D045744:Cell Line, Tumor; D003106:Colon / Q000187:drug effects / Q000473:pathology; D003110:Colonic Neoplasms / Q000628:therapy*; D004032:Diet; D015232:Dinoprostone / Q000097:blood; D004195:Disease Models, Animal; D002149:Energy Intake; D005472:Fluorouracil / Q000627:therapeutic use; D007155:Immunologic Factors; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000628:therapy*; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
chemical_list: D000970:Antineoplastic Agents; D001786:Blood Glucose; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D015850:Interleukin-6; D042461:Vascular Endothelial Growth Factor A; D015232:Dinoprostone; D005472:Fluorouracil